Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
23
TARA Quote, Financials, Valuation and Earnings
Last price:
$5.11
Seasonality move
:
-16.66%
Day range:
$4.86 - $5.13
52-week range:
$2.77 - $7.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.43x
Volume:
511.5K
Avg. volume:
1.3M
1-year change:
19.11%
Market cap:
$280.2M
Revenue:
--
EPS (TTM):
-$1.34
Analysts' Opinion
-
Consensus RatingProtara Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.71, Protara Therapeutics, Inc. has an estimated upside of 403.22% from its current price of $5.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing -- downside risk from its current price of $5.11.
Fair Value
-
According to the consensus of 6 analysts, Protara Therapeutics, Inc. has 403.22% upside to fair value with a price target of $25.71 per share.
TARA vs. S&P 500
-
Over the past 5 trading days, Protara Therapeutics, Inc. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Protara Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protara Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Protara Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Protara Therapeutics, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Protara Therapeutics, Inc. reported earnings per share of -$0.38.
Enterprise value:
124.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$625K
Return On Assets:
-33.35%
Net Income Margin (TTM):
--
Return On Equity:
-35.96%
Return On Invested Capital:
-35.09%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$711K | -$332K | -$625K | -$82K | -$93K | |
| Operating Income | -$43.6M | -$49.2M | -$64.5M | -$14.3M | -$19.1M | |
| EBITDA | -$42.9M | -$48.8M | -$63.9M | -$14.2M | -$19M | |
| Diluted EPS | -$3.57 | -$2.41 | -$1.34 | -$0.48 | -$0.38 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $93.1M | $86.1M | $68.7M | $172.2M | $159.5M | |
| Total Assets | $172.6M | $113.3M | $79M | $181.5M | $209.5M | |
| Current Liabilities | $4.3M | $5.7M | $6.1M | $11M | $10.9M | |
| Total Liabilities | $10.7M | $11.2M | $10.6M | $14.3M | $13.1M | |
| Total Equity | $161.9M | $102.1M | $68.3M | $167.1M | $196.4M | |
| Total Debt | $6.4M | $5.5M | $4.5M | $3.4M | $2.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$37.6M | -$35.8M | -$56.4M | -$9.3M | -$17M | |
| Cash From Investing | $53.1M | $19.2M | -$139.5M | $22.5M | -$26.9M | |
| Cash From Financing | -$91K | $139.9M | $82.7M | $97.8M | $81M | |
| Free Cash Flow | -$37.6M | -$35.9M | -$56.5M | -$9.3M | -$17M | |
TARA
Sector
Market Cap
$280.2M
$23.9M
Price % of 52-Week High
--
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-28.93%
-1.9%
1-Year Price Total Return
19.11%
-18.29%
Beta (5-Year)
1.496
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.08
200-day SMA
Buy
Level
$4.81
Bollinger Bands (100)
Sell
Level
5.14 - 6.66
Chaikin Money Flow
Sell
Level
-137.8M
20-day SMA
Sell
Level
$5.30
Relative Strength Index (RSI14)
Sell
Level
43.05
ADX Line
Sell
Level
23.28
Williams %R
Neutral
Level
-55.0725
50-day SMA
Sell
Level
$6.03
MACD (12, 26)
Sell
Level
-0.26
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
85M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.9389)
Buy
CA Score
(Annual)
Level (0.0195)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (6.2214)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, TARA has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TARA average analyst price target in the past 3 months is $25.71.
-
Where Will Protara Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protara Therapeutics, Inc. share price will rise to $25.71 per share over the next 12 months.
-
What Do Analysts Say About Protara Therapeutics, Inc.?
Analysts are divided on their view about Protara Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protara Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is Protara Therapeutics, Inc.'s Price Target?
The price target for Protara Therapeutics, Inc. over the next 1-year time period is forecast to be $25.71 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TARA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protara Therapeutics, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TARA?
You can purchase shares of Protara Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protara Therapeutics, Inc. shares.
-
What Is The Protara Therapeutics, Inc. Share Price Today?
Protara Therapeutics, Inc. was last trading at $5.11 per share. This represents the most recent stock quote for Protara Therapeutics, Inc.. Yesterday, Protara Therapeutics, Inc. closed at $5.11 per share.
-
How To Buy Protara Therapeutics, Inc. Stock Online?
In order to purchase Protara Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TARA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TARA
Sector
P/E ratio
--
21.37x
PEG ratio
--
-0.01x
P/B ratio
1.43x
1.72x
Price / LTM sales
--
1.44x
Growth Metrics
TARA
Sector
Revenue growth
--
3.44%
Earnings growth
22.19%
14.97%
Revenue (5-year growth)
--
6.27%
Earnings forecast
-$0.39
-$0.22
Profitability
TARA
Sector
Profitability FY 2025
-$362K
$2.4M
Return on invested capital
-35.09%
-33.43%
Return on assets
-33.35%
-29.45%
Return on equity
-35.96%
-40.29%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
May
7
Estimated Next Earnings Date
Feb
9
Balance Sheet
TARA
Sector
Total cash
$155.6M
$25.6M
Short term investments
$7.5M
$22.7M
Total assets
$209.5M
$70.4M
Long term debt
$2.1M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
